A clinical trial in now enrolling patients to evaluate the effectiveness of Rituxan (rituximab) plus the addition of Leukine (sargramostim) for patients with follicular B-cell lymphoma that has recurred. This type of lymphoma is categorized as a low-grade non-Hodgkin's lymphoma (NHL) that comprises 30 percent of all cases.
Rituxan is commonly used in the treatment of various forms of NHL. Researchers are continuing to evaluate ways to improve the anti-cancer responses to Rituxan. One such drug called Leukine is a growth factor which can stimulate the immune system to help fight disease. Leukine is also thought to have properties that improve Rituxan's cancer-killing effects based on previous clinical trials.
One group of patients in the study will be treated with Leukine plus Rituxan, and the other group will be treated with Rituxan alone. Patients will be assessed according to how their cancer responds to treatment.
For more information on enrollment for this clinical trial, go to
